Themis Medicare is currently trading at Rs. 460.00, up by 0.35 points or 0.08% from its previous closing of Rs. 459.65 on the BSE.
The scrip opened at Rs. 457.75 and has touched a high and low of Rs. 460.00 and Rs. 441.00 respectively. So far 224 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 708.95 on 28-Oct-2016 and a 52 week low of Rs. 380.00 on 28-Aug-2017.
Last one week high and low of the scrip stood at Rs. 469.95 and Rs. 441.00 respectively. The current market cap of the company is Rs. 416.13 crore.
The promoters holding in the company stood at 66.95%, while Institutions and Non-Institutions held 0.01% and 33.04% respectively.
Themis Medicare has received an approval for entering into Joint Venture Agreement (JVA) with Global Pharmatech for incorporating a new Joint Venture Company (JVC) subject to statutory permissions and formalities. The board of directors at its meeting held on September 27, 2017 approved for the same.
Themis Medicare is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and Formulations. The company is also engaged in supplying their research formulations to well-known Pharmaceutical companies in India namely Alkem Lab, Fulford, Intas Pharmaceuticals, IPCA Lab., Cadila Healthcare, Aristo Pharma, Mankind Pharma, Shreya Lifesciences, Nicholas Piramal, Unichem Lab, etc.
